Brody · Psychiatry research 1999 · Uncontrolled pre-post imaging study · n=16

Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine.

Cited 301 times in the scientific literature.

Level 4 - case-series / case-control

Single-arm pre-post study without a placebo or healthy control comparison group.

PubMed 10641577 · doi:10.1016/s0925-4927(99)00034-7 · record verified 2026-08-29

What was done

Sixteen outpatients with major depressive disorder underwent [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) coregistered with MRI before and after open-label treatment with paroxetine (target dose 40 mg/day). Regions of interest were traced by a blinded rater. Treatment response was defined as a >50% decrease on the Hamilton Depression Rating Scale (HAM-D) plus a Clinical Global Improvement rating of 'much' or 'very much' improved, resulting in 9 responders and 7 non-responders.

What was found

Responders demonstrated significantly greater reductions in normalized ventrolateral prefrontal cortex (VLPFC) and orbitofrontal cortex (OFC) metabolism compared to non-responders. Changes in HAM-D scores positively correlated with metabolic changes in the VLPFC and inferior frontal gyrus (IFG). Pre-treatment hypometabolism in the left ventral anterior cingulate gyrus was associated with subsequent positive treatment response. No significant treatment-response effects were detected in the dorsolateral prefrontal cortex or IFG, and no laterality interactions were found. The abstract does not provide exact numerical metabolic values, effect sizes, or p-values.

Why it matters

This study provides mechanistic evidence linking selective serotonin reuptake inhibitor response to metabolic normalization within ventral prefrontal-subcortical circuits.

Limits

The sample size is very small (n=16, with only 9 responders), creating a high risk of false-positive or imprecise findings. There was no placebo or healthy control group to account for regression to the mean, scan-rescan variability, or non-pharmacological time effects. The abstract also omits quantitative measurements and statistical test values.

Cited by